The impact of a disease management programme for type 2 diabetes on health-related quality of life: multilevel analysis of a cluster-randomised controlled trial

Table 2 EQ-VAS at baseline, values for selected subgroups (intention-to-treat analysis population)

Subgroup 1/subgroup 2	No of participants, subgroup 1/subgroup 2	EQ-VAS, mean [CI], subgroup 1	EQ-VAS, mean [CI], subgroup 2	p value^a
Overall study population	1464	70.1 [69.1;71.0]		–
Intervention/control	639/825	69.4 [68.0;70.8]	70.6 [69.3;71.8]	0.231
Female/male	700/764	68.4 [67.0;69.8]	71.6 [70.3;72.8]	0.001
No manifestation of coronary heart disease^b/ any manifestation of coronary heart disease	1253/211	70.6 [69.6;71.6]	66.6 [64.1;69.2]	0.003
No macrovascular diabetic complication^c/ any macrovascular diabetic complication	1108/356	71.4 [70.3;72.4]	66.0 [64.1;68.0]	< 0.001
Living with a partner/ living alone	1111/318	71.0 [69.9;72.0]	66.8 [64.8;68.8]	< 0.001
Non Austrian/Austrian	80/1377	65.1 [60.6;69.7]	70.3 [69.4;71.3]	0.029
No higher education/ higher education	1327/117	69.9 [68.9;70.9]	72.1 [68.9;75.4]	0.202
Working fulltime/ not working fulltime	1255/202	69.7 [68.7;70.7]	72.4 [69.9;74.9]	0.050

^aIndependent T Test or Welch-Test, respectively
^bMyocardial infarction and/or PTCA/stenting and/or coronary bypass
^cMyocardial infarction and/or PTCA/stenting and/or coronary bypass and/or stroke and/or carotid surgery and/or amputation/gangrene and/or peripheral artery bypass or PTA

ISSN: 1758-5996